104 Les biomarqueurs moléculaires en oncologie
2. Mahgoud A, Idle JR, Dring LG, et al. (1977) Polymorphic hydroxylation of debrisoquine
l l
in man. Lancet 2: 584-6
3. http://www.1000genomes.org/home
4. Relling MV, Gardner EE, Sandborn WJ, et al. (2011) Clinical pharmacogenetics
implementation consortium guidelines for thiopurine methyltransferase genotype and
thiopurine dosing. Clin Pharmacol Ther 89: 387-91
5. Van der Akker-Van Marle ME, Gurwitz D, Detmar SB, et al. (2006) Cost-effectiveness
of pharmacogenomics in clinical practice: a case study of thiopurine methyl transferase
genotyping in acute lymphoblastic leukemia in europe. Pharmacogenomics 7: 783-92
6. Tavadia SM, Mydlarski PR, Reis MD, et al. (2000) Screening for azathioprine toxicity: a
l l
pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 42: 628-32
7. Pavlovic S (2009) TMPT gene polymorphisms: on the doorstep of personalized medicine.
Indian J Med Res 129: 478-80
8. Beutler E, Racial AM (1998) Variability in the UDP-glucuronosyltransferase 1 (UGT1A1)
promoter: A balanced plolumorphism for regulation of bilirubin métabolism ? Proc Natl
Acad Sci 95: 8170-4
9. Kurose K, Sugiyama E, Saito Y (2012) Population differences in malor functionnal
polymorphisms of pharmacokinetics/pharmacdynamics-related genes in eastern asians
and europeans : implications in the clinical trials for novel drug development. Drug Meta
Pharmcokinet 27: 9-54
10. Rouits E, Boisdron-Celle M, Dumont A, et al. (2004) Relevance of different UGT1A1
polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75
patients. Clin Cancer Res 10: 5151-9
11. Innocenti F, Undevia SD, Iyer L, et al. (2004) Genetic variants in the
UDP-glucuronyltrasnferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
J Clin Oncol 22: 1382-8
12. Iyer L, Das S, Janisch L, et al. (2002) UGT1A1*28 polymorphism as a determinant of
irinotecan disposition and toxicity. Pharmacogenomics J 2: 43-4
13. Ando Y, Saka H, Ando M, et al. (2000) Polymorphism of UDP-glucuronyl-transferase
gene and irinotecan toxicity: A pharmogenetic analysis. Cancer Res 60: 6921-6
14. Capitain O, Metges JP, Adenis A, et al. (2010) Pharmacokinetic and pharmacogenetic
approach to improve dose intensity and tolerance of FOLFIRI+Cetuximab in patients with
metastatic CRC. ASCO GI San Francisco USA, janvier
15. Satoh T, Ura T, Yamada Y, et al. (2011) Genotype-directed, dose-finding study of irinotecan
l l
in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102:
1868-73
16. Largillier R, Etienne-Grimaldi MC, Formento JL, et al. l l (2006) Pharmacogenetics of
capecitabine in advanced breast cancer patients. Clin Cancer Res 12(18): 5496-502
17. Van Kuilenburg ABP, Vreken P, Abeling NGGM, et al. (1999) Genotype and phenotype in
l l
patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104: 1-9
18. Wei X, Elizondo G, Sapone A, et al. (1998) Characterization of the human dihydropyrimidine
dehyrdogenase gene. Genomics 5: 391-400
19. Wei X, McLeod HL, McMurrough J, et al. (1996) Molecular basis of the human
dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98:
610-5
20. Morel A, Boisdron-Celle M, Fey L, et al. (2006)
l l
Clinical relevance of different
dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil
tolerance. Mol Cancer Ther 5: 2895-904
21. Mc Leod HL, Collie-Duguid ESR, Vrecken P, et al. l l (1998) Nomenclature for human
DPYD alleles. Pharmacogenetics 8: 455-9
22. Van Kuilenburg AB, Muller EW, Haasjes J, et al. (2001)
l l
Lethal outcome of a patient
with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration
2. Mahgoud A, Idle JR, Dring LG, et al. (1977) Polymorphic hydroxylation of debrisoquine
l l
in man. Lancet 2: 584-6
3. http://www.1000genomes.org/home
4. Relling MV, Gardner EE, Sandborn WJ, et al. (2011) Clinical pharmacogenetics
implementation consortium guidelines for thiopurine methyltransferase genotype and
thiopurine dosing. Clin Pharmacol Ther 89: 387-91
5. Van der Akker-Van Marle ME, Gurwitz D, Detmar SB, et al. (2006) Cost-effectiveness
of pharmacogenomics in clinical practice: a case study of thiopurine methyl transferase
genotyping in acute lymphoblastic leukemia in europe. Pharmacogenomics 7: 783-92
6. Tavadia SM, Mydlarski PR, Reis MD, et al. (2000) Screening for azathioprine toxicity: a
l l
pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 42: 628-32
7. Pavlovic S (2009) TMPT gene polymorphisms: on the doorstep of personalized medicine.
Indian J Med Res 129: 478-80
8. Beutler E, Racial AM (1998) Variability in the UDP-glucuronosyltransferase 1 (UGT1A1)
promoter: A balanced plolumorphism for regulation of bilirubin métabolism ? Proc Natl
Acad Sci 95: 8170-4
9. Kurose K, Sugiyama E, Saito Y (2012) Population differences in malor functionnal
polymorphisms of pharmacokinetics/pharmacdynamics-related genes in eastern asians
and europeans : implications in the clinical trials for novel drug development. Drug Meta
Pharmcokinet 27: 9-54
10. Rouits E, Boisdron-Celle M, Dumont A, et al. (2004) Relevance of different UGT1A1
polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75
patients. Clin Cancer Res 10: 5151-9
11. Innocenti F, Undevia SD, Iyer L, et al. (2004) Genetic variants in the
UDP-glucuronyltrasnferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
J Clin Oncol 22: 1382-8
12. Iyer L, Das S, Janisch L, et al. (2002) UGT1A1*28 polymorphism as a determinant of
irinotecan disposition and toxicity. Pharmacogenomics J 2: 43-4
13. Ando Y, Saka H, Ando M, et al. (2000) Polymorphism of UDP-glucuronyl-transferase
gene and irinotecan toxicity: A pharmogenetic analysis. Cancer Res 60: 6921-6
14. Capitain O, Metges JP, Adenis A, et al. (2010) Pharmacokinetic and pharmacogenetic
approach to improve dose intensity and tolerance of FOLFIRI+Cetuximab in patients with
metastatic CRC. ASCO GI San Francisco USA, janvier
15. Satoh T, Ura T, Yamada Y, et al. (2011) Genotype-directed, dose-finding study of irinotecan
l l
in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102:
1868-73
16. Largillier R, Etienne-Grimaldi MC, Formento JL, et al. l l (2006) Pharmacogenetics of
capecitabine in advanced breast cancer patients. Clin Cancer Res 12(18): 5496-502
17. Van Kuilenburg ABP, Vreken P, Abeling NGGM, et al. (1999) Genotype and phenotype in
l l
patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104: 1-9
18. Wei X, Elizondo G, Sapone A, et al. (1998) Characterization of the human dihydropyrimidine
dehyrdogenase gene. Genomics 5: 391-400
19. Wei X, McLeod HL, McMurrough J, et al. (1996) Molecular basis of the human
dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98:
610-5
20. Morel A, Boisdron-Celle M, Fey L, et al. (2006)
l l
Clinical relevance of different
dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil
tolerance. Mol Cancer Ther 5: 2895-904
21. Mc Leod HL, Collie-Duguid ESR, Vrecken P, et al. l l (1998) Nomenclature for human
DPYD alleles. Pharmacogenetics 8: 455-9
22. Van Kuilenburg AB, Muller EW, Haasjes J, et al. (2001)
l l
Lethal outcome of a patient
with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration